8-K: Silexion Therapeutics Expands Funding Options and Reports Promising Preclinical Data for Pancreatic Cancer Treatment

Silexion Therapeutics enhances its financing flexibility with an amendment to its share purchase agreement and announces encouraging preclinical results for its SIL-204 candidate in combination with chemotherapy for pancreatic cancer.

Summary

• Silexion Therapeutics amended its share purchase agreement with White Lion Capital, introducing an accelerated purchase mechanism.
• This allows Silexion to request White Lion Capital to purchase up to 5% of the average daily trading volume at 99% of the lowest traded price during a two-hour period after acceptance of the purchase notice.
• The closing of such a sale will occur on the next business day following the notice.
• Silexion also announced positive preclinical data for its SIL-204 candidate, showing synergistic efficacy with first-line chemotherapy agents in pancreatic cancer treatment.
• SIL-204 demonstrated synergistic activity with 5-fluorouracil, irinotecan, and gemcitabine in human pancreatic tumor cell lines with KRAS G12D mutations.
• The combination of SIL-204 with 5-fluorouracil and irinotecan led to a significant reduction in cancer cell confluence compared to chemotherapy alone (p < 0.0005).
• Silexion plans to initiate toxicology studies with SIL-204 in the coming months and advance it into Phase 2/3 clinical trials in the first half of 2026, focusing on locally advanced pancreatic cancer (LAPC).

Sentiment

Score: 8

Explanation: The document presents positive preclinical data and enhanced financial flexibility, suggesting a favorable outlook for the company.

Positives

• The amendment to the share purchase agreement provides Silexion with more flexible access to capital.
• The preclinical data for SIL-204 is promising, suggesting potential for improved treatment outcomes in pancreatic cancer.
• The synergistic activity of SIL-204 with multiple chemotherapy agents broadens its potential application.
• Advancing SIL-204 into Phase 2/3 clinical trials in the first half of 2026 represents a significant milestone.

Risks

• The success of SIL-204 in preclinical studies does not guarantee success in clinical trials.
• The company's ability to obtain additional capital is subject to market conditions and investor sentiment.
• Regulatory hurdles and compliance complexities could delay or prevent the approval of SIL-204.
• The company's future success depends on its ability to successfully complete preclinical studies and initiate clinical trials.

Future Outlook

Silexion plans to initiate toxicology studies with SIL-204 in the coming months and advance it into Phase 2/3 clinical trials in the first half of 2026, focusing initially on locally advanced pancreatic cancer (LAPC). In parallel, the company plans to initiate preclinical studies for SIL-204 in colorectal cancer models.

Management Comments

• The synergy demonstrated between SIL-204 and first-line chemotherapies underscores its potential to enhance existing treatment regimens and address significant unmet needs across multiple oncology indications, said Ilan Hadar, Chairman and CEO of Silexion.

Industry Context

The development of SIL-204 targets KRAS-mutated cancers, which are notoriously difficult to treat and represent a significant unmet need in oncology. The synergistic activity with existing chemotherapies could position SIL-204 as a valuable addition to current treatment regimens.

Comparison to Industry Standards

• LODER (siG12DLoder), Silexion's first-generation product, showed a significant improvement in overall survival in the siRNA plus chemotherapy arm compared to chemotherapy alone in Phase 2 trials.
• KRAS is a validated target in oncology, with companies like Mirati Therapeutics (now part of Bristol Myers Squibb) and Amgen developing KRAS inhibitors.
• Silexion's approach of using RNA interference (RNAi) to target KRAS mutations is distinct from small molecule inhibitors and could offer advantages in terms of specificity and safety.

Stakeholder Impact

• Shareholders may benefit from the potential for increased stock value due to positive preclinical results and enhanced financial flexibility.
• Patients with pancreatic cancer could benefit from the development of SIL-204 as a potential new treatment option.
• Employees may benefit from the company's growth and success.

Next Steps

• Initiate toxicology studies with SIL-204 in the coming months.
• Advance SIL-204 into Phase 2/3 clinical trials in the first half of 2026, focusing on locally advanced pancreatic cancer (LAPC).
• Initiate preclinical studies for SIL-204 in colorectal cancer models.

Key Dates